Biodesix opened higher at $10.17, compared with its previous close of $10.12. In the last trading session, the stock traded between $9.70 and $10.87. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Biodesix is now worth
$ 6.22
Resulting in a loss of
$ 93.78 (93.78%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.31 (-3.06%)
Day High
$10.87
Day Low
$9.70
Day Open
$10.17
Prev Close
$10.12
Volume
2,76,166
1W Return
-54.22%
1M Return
-61.68%
3M Return
-59.48%
6M Return
-39.11%
1Y Return
17.63%
Market Cap ($ Mn)
109
PE Ratio
-
PB Ratio
30.89
PEG Ratio
-
ROE
-610.40%
ROCE
-37.33%
EPS (TTM)
$-0.73
1 Week
-54.22%
1 Month
-61.68%
3 Months
-59.48%
6 Months
-39.11%
9 Months
-5.22%
Biodesix shares fall 50% as firm cuts FY26 revenue guidance
Biodesix shares fell 57% to $8.53 after Q3 revenue of $24.0 million missed expectations. Full-year 2026 revenue guidance cut to $101-$103 million from $108-$114 million. CEO cites fewer sales reps and seasonality as key drivers for the shortfall. Kirby McInerney LLP and Johnson Fistel initiate investigations into securities claims.
3 days agoHC Wainwright maintains Buy on Biodesix, cuts price target to $34
HC Wainwright & Co. maintains a Buy rating on Biodesix. Price target lowered from $38 to $34 by analyst Yi Chen. Rating action indicates continued positive outlook despite valuation cut.
3 days agoLake Street maintains Buy on Biodesix, cuts price target to $30
Lake Street analyst Thomas Flaten lowered Biodesix's price target from $40 to $30. The firm maintained a Buy rating on the stock following the revision. The price target cut represents a 25% reduction from the previous estimate.
6 days agoBiodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%
Shares fell 29.44% after Q3 FY26 revenue of $24 million missed estimates by 12.4%. Full-year revenue guidance cut to $101-103 million from $108-114 million previously. Diagnostic testing revenue rose 16% to $23 million, but average revenue per test fell 6%. Net loss improved 8% YoY to $8 million; adjusted EBITDA loss narrowed 16%. Shortfall attributed to fewer sales reps than planned and project delays.
6 days agoBiodesix notes CHEST framework integrating Nodify Lung tests for care
CHEST published "Building a Lung Nodule Program: From Detection to Diagnosis". Framework includes six steps for comprehensive lung nodule programs. Validates biomarker testing like Nodify Lung for risk stratification. Developed by multidisciplinary panel of US medical specialists.
24 days agoBiodesix adds AI-powered imaging test to expand lung cancer risk screening
Biodesix adds Digital Diagnostics to its Lung Diagnostics strategy, creating a multimodal platform. First product is a radiomics-based test for lung nodule risk assessment developed with Vanderbilt. Initial data presentation scheduled for RSNA Annual Meeting on December 3, 2026. Commercial availability anticipated in 2028 following STRATIFY study commencement in Q4 2026.
24 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $717.71 | -0.07% | $2,65,923.04M | 33.49 | |
| $235.31 | -0.34% | $1,65,547.88M | 38.52 | |
| $702.59 | +0.85% | $55,354.26M | 39.00 | |
| $176.95 | -0.52% | $49,887.34M | 30.34 | |
| $319.82 | +2.51% | $46,375.50M | - | |
| $470.90 | -0.97% | $46,282.88M | 104.98 | |
| $274.53 | -0.23% | $45,242.54M | 32.52 | |
| $1,749.01 | -0.14% | $34,787.81M | 31.52 | |
| $212.93 | -0.92% | $32,195.02M | 40.22 | |
| $372.23 | +0.36% | $30,225.08M | 27.72 | |
| $258.69 | +0.10% | $28,460.82M | 25.77 | |
| $154.78 | -0.37% | $20,939.57M | - |
An investment of $100 made 5 years ago in Biodesix is now worth
$ 6.22
Resulting in a loss of
$ 93.78 (93.78%)
Note: Past profits do not guarantee future returns.
